Company Overview

Seer, Inc. (ticker: SEER) is a life sciences technology company operating in the proteomics and biotechnology research tools industries. The company develops and commercializes platforms designed to enable deep, unbiased analysis of the proteome, supporting biological discovery, drug development, and clinical research. Seer’s core value proposition is its ability to overcome traditional limitations of proteomic analysis, particularly the challenge of detecting low-abundance proteins in complex biological samples such as blood plasma.

The company’s primary revenue is generated from the sale of its proprietary Proteograph™ Product Suite, which integrates engineered nanoparticles, consumables, software, and analytical workflows. Seer serves pharmaceutical and biotechnology companies, academic research institutions, and clinical research organizations. Founded in 2017 and initially incubated within Illumina, Inc., Seer became an independent company and completed its initial public offering in 2020, positioning itself as a specialized platform provider in the rapidly growing proteomics market.

Business Operations

Seer operates primarily through a single reportable operating segment focused on the development and commercialization of its Proteograph™ Platform, which includes instruments, nanoparticle consumables, assay kits, and data analysis software. Revenue is generated through instrument sales, recurring consumables, and service-related offerings, creating an installed-base-driven business model with repeat usage potential. The platform leverages proprietary engineered nanoparticles that differentially bind proteins, enabling scalable and reproducible proteomic profiling.

Operations are centered in the United States, with commercial reach extending to international research markets through direct sales and distribution partners. Seer maintains internal capabilities across research and development, manufacturing oversight, quality control, and commercial support. As of publicly available disclosures, the company does not report material joint ventures, and its operations are conducted primarily through the parent entity rather than a complex subsidiary structure.

Strategic Position & Investments

Seer’s strategy focuses on expanding adoption of its Proteograph™ Platform by increasing the depth, throughput, and accessibility of proteomic analysis. Growth initiatives include expanding the menu of nanoparticle chemistries, enhancing software and data analytics capabilities, and increasing automation to support large-scale population studies. The company has emphasized partnerships with pharmaceutical companies and research consortia to validate its technology in drug discovery and biomarker development workflows.

The company continues to invest heavily in research and development to maintain technological differentiation in an increasingly competitive proteomics landscape. While Seer has not disclosed major transformative acquisitions as of the most recent public filings, it has made targeted investments in platform enhancements and ecosystem development. Its strategic positioning centers on being an enabling technology provider rather than a therapeutics developer, aligning its long-term growth with broader advances in precision medicine and systems biology.

Geographic Footprint

Seer is headquartered in Redwood City, California, within the United States, and conducts the majority of its research, development, and corporate functions from this location. Its primary customer base is concentrated in North America, particularly among U.S.-based pharmaceutical and biotechnology companies and leading academic institutions.

Internationally, Seer has established a growing presence in Europe and parts of Asia-Pacific through direct commercial activities and distributor relationships. While international revenue represents a smaller portion of total sales compared to the domestic market, the company has identified global expansion as a key long-term opportunity, particularly in regions with strong investments in biomedical research and population-scale proteomics initiatives.

Leadership & Governance

Seer is led by an executive team with experience across life sciences, genomics, and technology commercialization. The leadership emphasizes long-term platform innovation, scientific rigor, and partnerships with industry and academic stakeholders to drive adoption of proteomics at scale. Governance follows U.S. public company standards, with oversight by an independent board of directors and compliance with SEC filings and reporting requirements.

Key executives include:

• Omkar Kulkarni – Chief Executive Officer
• Jon Odegard – Chief Financial Officer
• Nerina Kisalus – Chief Legal Officer and Secretary
• Kelly H. Williams – Chief Operating Officer
• Dylan E. Jones – Chief Scientific Officer

The leadership team’s strategic vision centers on establishing Seer’s platform as a foundational tool for biological insight, analogous to the role of next-generation sequencing in genomics, while maintaining disciplined capital allocation and operational execution as a publicly traded company.